Skip to content
2000
image of Efficacy and Safety of Combining Camrelizumab with Tyrosine Kinase Inhibitors in Advanced Nasopharyngeal Carcinoma: A Meta-Analysis
file format pdf download PDF

Abstract

Introduction

Nasopharyngeal carcinoma (NPC) is a malignancy of the head and neck with high prevalence in southern China and Southeast Asia. It is histopathologically diverse and often associated with Epstein-Barr virus (EBV) infection, along with genetic and environmental risk factors. Standard treatment involves radiotherapy, supplemented by chemotherapy in advanced stages. However, for recurrent or metastatic NPC, newer therapeutic strategies, such as combining Camrelizumab—a PD-1 monoclonal antibody—with tyrosine kinase inhibitors (TKIs) have emerged as promising options. This systematic review and meta-analysis evaluates the efficacy and safety of this combination in patients with advanced NPC.

Methods

A comprehensive literature search was conducted in PubMed, Cochrane Central Register of Controlled Trials, Scopus, and Web of Science databases up to June 2024. Inclusion criteria encompassed clinical trials or cohort studies reporting on the efficacy and safety of Camrelizumab plus TKIs in advanced or recurrent NPC. Exclusion criteria included animal studies, case reports, and reviews. Both randomized and non-randomized studies were included due to limited data availability. Study quality was assessed using the Cochrane Risk of Bias (ROB1) tool. Data extraction focused on treatment outcomes, adverse events, and survival rates. Statistical analysis was performed using RevMan 5.4.

Results

Five studies encompassing 217 patients met the inclusion criteria. Pooled analysis showed a partial response (PR) rate of 50% (95% CI: 36%–65%), while a complete response was 10% (95% CI: 0%–21%). Stable disease was observed in 19% (95% CI: 5%–33%), and progressive disease in 10% (95% CI: 0%–20%). One-year progression-free survival (PFS) and overall survival (OS) rates were 46% (95% CI: 37%–54%) and 78% (95% CI: 62%–94%), respectively. Common treatment-related adverse events included anemia (62%), nausea (52%), leukopenia (46%), hypertension (45%), and neutropenia (43%).

Conclusion

The combination of Camrelizumab and TKIs appears to be an effective and well-tolerated treatment for patients with recurrent or advanced NPC, offering favorable response rates and survival outcomes. Further large-scale, randomized studies are warranted to validate these findings and refine treatment protocols.

© 2025 Bentham Science Publishers The Author(s). Published by Bentham Science Publishers.
This is an open access article published under CC BY 4.0 https://creativecommons.org/licenses/by/4.0/legalcode
Loading

Article metrics loading...

/content/journals/cdrr/10.2174/0125899775422297251128082623
2025-12-30
2026-02-25

  • From This Site

    /content/journals/cdrr/10.2174/0125899775422297251128082623
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

/deliver/fulltext/cdrr/10.2174/0125899775422297251128082623/BMS-CDRR-2025-181.html?itemId=/content/journals/cdrr/10.2174/0125899775422297251128082623&mimeType=html&fmt=ahah

References

  1. Chen Y.P. Chan A.T.C. Le Q.T. Blanchard P. Sun Y. Ma J. Nasopharyngeal carcinoma. Lancet 2019 394 10192 64 80 10.1016/S0140‑6736(19)30956‑0 31178151
    [Google Scholar]
  2. Cao S.M. Simons M.J. Qian C.N. The prevalence and prevention of nasopharyngeal carcinoma in China. Chin. J. Cancer 2011 30 2 114 119 10.5732/cjc.010.10377 21272443
    [Google Scholar]
  3. Berry M.P. Smith C.R. Brown T.C. Jenkin R.D.T. Rider W.D. Nasopharyngeal carcinoma in the young. Int. J. Radiat. Oncol. Biol. Phys. 1980 6 4 415 421 10.1016/0360‑3016(80)90054‑1 7390922
    [Google Scholar]
  4. Sham J.S.T. Poon Y.F. Wei W.I. Choy D. Nasopharyngeal carcinoma in young patients. Cancer 1990 65 11 2606 2610 10.1002/1097‑0142(19900601)65:11<2606:AID‑CNCR2820651135>3.0.CO;2‑U 2337878
    [Google Scholar]
  5. Shah A.B. Nagalli S. Nasopharyngeal carcinoma. StatPearls. Treasure Island, FL StatPearls Publishing 2024
    [Google Scholar]
  6. Pathmanathan R. Prasad U. Sadler R. Flynn K. Raab-Traub N. Clonal proliferations of cells infected with Epstein-Barr virus in preinvasive lesions related to nasopharyngeal carcinoma. N. Engl. J. Med. 1995 333 11 693 698 10.1056/NEJM199509143331103 7637746
    [Google Scholar]
  7. Ung A. Chen C.J. Levine P.H. Familial and sporadic cases of nasopharyngeal carcinoma in Taiwan. Anticancer Res. 1999 19 1B 661 665 10216473
    [Google Scholar]
  8. Lu C.C. Chen J.C. Tsai S.T. Nasopharyngeal carcinoma–susceptibility locus is localized to a 132 kb segment containing HLA‐A using high‐resolution microsatellite mapping. Int. J. Cancer 2005 115 5 742 746 10.1002/ijc.20946 15729690
    [Google Scholar]
  9. Yuan J.M. Wang X.L. Xiang Y.B. Gao Y.T. Ross R.K. Yu M.C. Preserved foods in relation to risk of nasopharyngeal carcinoma in Shanghai, China. Int. J. Cancer 2000 85 3 358 363 10.1002/(SICI)1097‑0215(20000201)85:3<358:AID‑IJC11>3.0.CO;2‑E 10652427
    [Google Scholar]
  10. Chang E.T. Adami H.O. The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol. Biomarkers Prev. 2006 15 10 1765 1777 10.1158/1055‑9965.EPI‑06‑0353 17035381
    [Google Scholar]
  11. Han L. Lin S.J. Pan J.J. Prognostic factors of 305 nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy. Chin. J. Cancer 2010 29 2 145 150 10.5732/cjc.009.10332 20109341
    [Google Scholar]
  12. Grégoire V. Ang K. Budach W. Delineation of the] neck node levels for head and neck tumors: A 2013 update. DAHANCA, EORTC, HKNPCSG, NCIC CTG, NCRI, RTOG, TROG consensus guidelines. Radiother. Oncol. 2014 110 1 172 181 10.1016/j.radonc.2013.10.010 24183870
    [Google Scholar]
  13. Lee N. Harris J. Garden A.S. Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: Radiation therapy oncology group phase II trial 0225. J. Clin. Oncol. 2009 27 22 3684 3690 10.1200/JCO.2008.19.9109 19564532
    [Google Scholar]
  14. Blanchard P. Nguyen F. Moya-Plana A. [New developments in the management of nasopharyngeal carcinoma]. Cancer Radiother. 2018 22 6-7 492 495 10.1016/j.canrad.2018.06.003 30087054
    [Google Scholar]
  15. Mnejja W. Toumi N. Fourati N. [Neoadjuvant chemotherapy with concurrent chemoradiotherapy in the treatment of nasopharyngeal cancer: Southern Tunisian experience]. Bull. Cancer 2018 105 5 450 457 10.1016/j.bulcan.2018.02.004 29650393
    [Google Scholar]
  16. Toumi N. Ennouri S. Charfeddine I. Daoud J. Khanfir A. Prognostic factors in metastatic nasopharyngeal carcinoma. Rev. Bras. Otorrinolaringol. 2022 88 2 212 219 32690385
    [Google Scholar]
  17. Hartmann J. Haap M. Kopp H.G. Lipp H.P. Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects. Curr. Drug Metab. 2009 10 5 470 481 10.2174/138920009788897975 19689244
    [Google Scholar]
  18. Fang W. Yang Y. Ma Y. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: Results from two single-arm, phase 1 trials. Lancet Oncol. 2018 19 10 1338 1350 10.1016/S1470‑2045(18)30495‑9 30213452
    [Google Scholar]
  19. Page M.J. McKenzie J.E. Bossuyt P.M. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ 2021 372 71 n71 10.1136/bmj.n71 33782057
    [Google Scholar]
  20. Cumpston M. Li T. Page M.J. Updated guidance for trusted systematic reviews: A new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Libr. 2019 10 10 ED000142 10.1002/14651858.ED000142 31643080
    [Google Scholar]
  21. The EndNote Team TET. Philadelphia, PA Clarivate 2013
    [Google Scholar]
  22. Ouzzani M. Hammady H. Fedorowicz Z. Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst. Rev. 2016 5 1 210 10.1186/s13643‑016‑0384‑4 27919275
    [Google Scholar]
  23. Slim K. Nini E. Forestier D. Kwiatkowski F. Panis Y. Chipponi J. Methodological index for non‐randomized studies (MINORS): Development and validation of a new instrument. ANZ J. Surg. 2003 73 9 712 716 10.1046/j.1445‑2197.2003.02748.x 12956787
    [Google Scholar]
  24. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing 2020
    [Google Scholar]
  25. Ding X. Hua Y.J. Zou X. Camrelizumab plus famitinib in patients with recurrent or metastatic nasopharyngeal carcinoma treated with PD-1 blockade: Data from a multicohort phase 2 study. EClinicalMedicine 2023 61 102043 10.1016/j.eclinm.2023.102043 37415845
    [Google Scholar]
  26. Ding X. Zhang W.J. You R. Camrelizumab plus apatinib in patients with recurrent or metastatic nasopharyngeal carcinoma: An open-label, single-arm, phase II study. J. Clin. Oncol. 2023 41 14 2571 2582 10.1200/JCO.22.01450 36735896
    [Google Scholar]
  27. Mo Y. Pan Y. Zhang B. Apatinib combined with camrelizumab in the treatment of recurrent/metastatic nasopharyngeal carcinoma: A prospective multicenter phase II study. Front. Immunol. 2024 14 1298418 10.3389/fimmu.2023.1298418 38239359
    [Google Scholar]
  28. Yuan L. Jia G.D. Lv X.F. Camrelizumab combined with apatinib in patients with first-line platinum-resistant or PD-1 inhibitor resistant recurrent/metastatic nasopharyngeal carcinoma: A single-arm, phase 2 trial. Nat. Commun. 2023 14 1 4893 10.1038/s41467‑023‑40402‑x 37580352
    [Google Scholar]
  29. Liang H. Jiang Y.F. Liu G.Y. Camrelizumab and apatinib plus induction chemotherapy and concurrent chemoradiotherapy in stage N3 nasopharyngeal carcinoma: A phase 2 clinical trial. Nat. Commun. 2024 15 1 1029 10.1038/s41467‑024‑45126‑0 38310101
    [Google Scholar]
  30. Alsafadi N. Alqarni M.S. Attar M. Mgarry R. Bokhari A. Nasopharyngeal cancer: Prevalence, outcome, and impact on health-related quality of life at princess norah oncology center, jeddah, saudi arabia. Cureus 2020 12 5 8199 10.7759/cureus.8199 32572356
    [Google Scholar]
  31. Brózik A Hegedüs C Erdei Z Tyrosine kinase inhibitors as modulators of ATP binding cassette multidrug transporters: Substrates, chemosensitizers or inducers of acquired multidrug resistance? Expert Opin Drug Metab Toxicol 2011 7 5 623 642 10.1517/17425255.2011.562892 21410427
    [Google Scholar]
  32. Aleid A.M. Almutairi G. Alrizqi R. The impact of statins on disease severity and quality of life in patients with psoriasis:] A systematic review and meta-analysis. Health Care 2024 12 15 1526 10.3390/healthcare12151526 39120229
    [Google Scholar]
  33. Abo Elnaga A.A. Serag I. Alsaied M.A. Efficacy and safety of tenapanor vs placebo in treating CKD patients on dialysis and with hyperphosphatemia: A systematic review and meta-analysis of 2251 patients. Int. Urol. Nephrol. 2024 57 6 1835 1850 10.1007/s11255‑024‑04316‑x 39702842
    [Google Scholar]
  34. Alrobeishy A.K. Alkharouby H.A. Ahmed R.A.A.M. Alsabt G.Y. Efficacy of raloxifene versus alendronate in postmenopausal women with osteoporosis: Systematic review and meta-analysis. J Adv Trends Med Res 2024 1 3 1094 1102 10.4103/ATMR.ATMR_212_24
    [Google Scholar]
/content/journals/cdrr/10.2174/0125899775422297251128082623
Loading
Efficacy and Safety of Combining Camrelizumab with Tyrosine Kinase Inhibitors in Advanced Nasopharyngeal Carcinoma: A Meta-Analysis
Bentham Science Publishers ; https://doi.org/10.2174/0125899775422297251128082623
/content/journals/cdrr/10.2174/0125899775422297251128082623
/content/journals/cdrr/10.2174/0125899775422297251128082623
Loading

Data & Media loading...

Supplements

PRISMA checklist is available as supplementary material on the publisher’s website along with the published article.

file format download Download

  • Article Type:     Research Article
Keywords: immunotherapy ; Camrelizumab ; nasopharyngeal carcinoma ; meta-analysis ; tyrosine kinase inhibitors

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test